Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2




FDA Renews Caution Against Mixing Simvastatin >20 mg/day and Amiodarone
Link ID 7650
Title FDA Renews Caution Against Mixing Simvastatin >20 mg/day and Amiodarone
Url http://www.medscape.com/viewarticle/578957?src=rss
Description Patients who take more than 20 mg/day of simvastatin in addition to amiodarone are at increased risk for rhabdomyolysis, the Food and Drug Administration has reminded physicians in the US. Medscape Medical News
Category Articles > Cardiology
Keywords
Date Aug 12, 2008
Contact Name
Email
Write a Review   Add to My Favorite   Refer it to Friend   Report Broken Link  

Average Visitor Rating: 0.00 (out of 5)
Number of ratings: 0 Votes
Visitor Rating

 Other links at Articles > Cardiology
1. PERISCOPE: Pioglitazone Prevents Atherosclerosis Progression in Diabetics
  A study of pioglitazone vs glimepiride suggests that pioglitazone produces meaningful changes in the cardiovascular risk profile for patients with diabetes and coronary artery disease. Medscape Medical News
Category:   Articles > Cardiology


2. Variations on the Theme of the Wenckebach Phenomenon (IV)
  What is happening after the premature ventricular complex (PVC)?
Medscape Cardiology
Category:   Articles > Cardiology


3. Revealing the Complexities and Uncertainties of the Cardiometabolic Syndrome: A Focus on Hypertensiv
  Learn about hypertension as a component of the cardiometabolic syndrome and its impact on cardiovascular disease progression and type 2 diabetes.
Category:   Articles > Cardiology


4. Vitamin K Supplements Reduce Progression of Insulin Resistance in Older Men
  A randomized trial shows that vitamin K supplementation for 36 months at doses attainable in the diet may reduce progression of insulin resistance in older men. Medscape Medical News
Category:   Articles > Cardiology


5. Aliskiren Reduces LVH to Same Extent as Losartan
  A combination of the new direct renin inhibitor aliskiren and losartan is no more effective than either drug alone in reducing left ventricular hypertrophy. Nevertheless, the results show that the two drugs are equivalent in this regard, providing the first solid data that aliskiren can reduce LV mass and adding to the body of knowledge about the new drug, says the lead investigator. Heartwire
Category:   Articles > Cardiology




Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS